Hims & Hers Launches New Peptide Treatments Despite Limited Evidence on Effectiveness
Hims & Hers Health has launched a new peptide and wellness treatment platform called Peptides+, offering customers access to five compounded treatments aimed at supporting energy, recovery and overall health. The announcement, made on November 18, 2026, comes as interest in longevity therapies grows, despite limited scientific evidence supporting many of their advertised benefits.
The initial offering includes sermorelin, NAD+, glutathione, vitamin B12 and L-carnitine. Customers must first complete a health assessment with a licensed medical provider, who will determine whether a treatment is appropriate and develop an individual plan.
Company Acknowledges Gaps in Clinical Evidence
Hims & Hers has acknowledged that researchers and healthcare providers still need more data to understand how these compounds work, which doses are appropriate and how effective they are for different health goals.
The company's Chief Medical Officer, Anant Vinjamoori, said there is not yet the level of clinical evidence typically available for established medicines. He added that the company sees a responsibility to help build a better understanding of these treatments through medical oversight and patient follow-ups.
The company plans to monitor customers' progress and adjust treatment plans when necessary.
Treatments Are Not FDA-Approved as Specific Products
The launch follows a change in US regulatory policy that allows certain pharmacies to compound some unapproved peptides under enforcement discretion. However, this does not mean the treatments have received formal approval from the US Food and Drug Administration (FDA).
Hims says its products are prepared by licensed US pharmacies and provided under medical supervision. The company also plans to introduce BPC-157 and TB-500 in the future, subject to applicable regulatory requirements.
Experts Warn About Safety and Unknown Risks
Medical experts have raised concerns about the lack of large-scale human clinical trials for several of these compounds. Questions remain about their long-term safety, effective doses, potential side effects and possible immune reactions.
The FDA has previously highlighted risks associated with certain compounded peptide products, including contamination and impurities. Experts also warn that anecdotal reports of benefits cannot replace reliable clinical evidence.
Through Peptides+, Hims & Hers is entering a growing wellness market while acknowledging that important scientific questions remain unanswered. The platform's success will depend not only on customer demand but also on whether stronger evidence supports the safety and effectiveness of these treatments.
More News:-

Recent Comments:
No comments yet.